Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biotechnology company built on its own antibody discovery technology, with major products including the eye treatment Eylea and, with partner Sanofi, the immunology drug Dupixent. A deep research pipeline and proprietary platforms have made it one of the more scientifically respected large-cap biotechs. Regeneron only recently began paying a dividend, so it has virtually no track record as an income stock, and the yield remains very small. The company prioritizes reinvestment in research and share buybacks, and its low score reflects that early-stage, minimal payout. For now this is best viewed as a growth biotech that has just started returning a little cash, not an established dividend name.